Strumento inattivo

Altre lingue Admedus Ltd Australian S.E.

Azioni

AU0000AHZDA7

Prezzo di chiusura Australian S.E. Altri mercati azionari
- ^AUD	-

10/04	Anteris Technologies raccoglie 23 milioni di dollari australiani per lo studio DurAVR	MT
13/03	Anteris dichiara risultati positivi dalle sperimentazioni umane della valvola cardiaca	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Anteris Technologies achieves breakthrough in triple valve replacement using DurAVRâ„¢	16/05
Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure with DurAVR	15/05
Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	18/04
Anteris Technologies Raises AU$23 Million for DurAVR Study	10/04
Anteris Declares Upbeat Results from Human Trials of Heart Valve	13/03
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Anteris talks market superiority of its biomimetic TAVR valve	31/10/23
Anteris Technologies Completes Enrollment for Heart Valve Device Study	17/10/23
Anteris Technologies Secures AU$1 Million Tax Rebate for 2022	13/10/23
Anteris Technologies Ltd(ASX:AVR) dropped from S&P Global BMI Index	18/09/23
Anteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023	12/09/23
Anteris Technologies Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
Anteris Technologies Ltd - DurAVR Demonstrates Exceptional Results in Second Valve-in-Valve Case	15/08/23
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case	14/08/23
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case	14/08/23
Anteris Technologies Ltd - Montefiore Health System Enrolls Patients in the US Early Feasibility Study	10/08/23
Anteris Technologies Commences American Depository Receipt Program	09/08/23
Anteris Technologies Commences US Early Feasibility Study	09/08/23
Montefiore Enrolls Patients for US Early Feasibility Study for Anteris Technologies' DurAVR THV	09/08/23
Anteris welcomes successful DurAVR valve-in-valve procedure	01/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Admedus Ltd Australian S.E.

Azioni

AU0000AHZDA7

Altre lingue

Filtri